Allianz Asset Management GmbH Reduces Position in Supernus Pharmaceuticals Inc (SUPN)

Allianz Asset Management GmbH trimmed its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 52.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 157,621 shares of the specialty pharmaceutical company’s stock after selling 174,121 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.31% of Supernus Pharmaceuticals worth $6,305,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Neumeier Poma Investment Counsel LLC increased its position in shares of Supernus Pharmaceuticals by 1.6% during the second quarter. Neumeier Poma Investment Counsel LLC now owns 890,740 shares of the specialty pharmaceutical company’s stock worth $38,391,000 after purchasing an additional 14,430 shares in the last quarter. Teachers Advisors LLC grew its holdings in Supernus Pharmaceuticals by 6.9% in the 2nd quarter. Teachers Advisors LLC now owns 466,060 shares of the specialty pharmaceutical company’s stock valued at $20,087,000 after buying an additional 29,939 shares in the last quarter. Royce & Associates LP grew its holdings in Supernus Pharmaceuticals by 22.3% in the 2nd quarter. Royce & Associates LP now owns 159,000 shares of the specialty pharmaceutical company’s stock valued at $6,853,000 after buying an additional 29,000 shares in the last quarter. Scout Investments Inc. grew its holdings in Supernus Pharmaceuticals by 2.6% in the 2nd quarter. Scout Investments Inc. now owns 166,675 shares of the specialty pharmaceutical company’s stock valued at $7,184,000 after buying an additional 4,225 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Supernus Pharmaceuticals by 790.8% in the 2nd quarter. Royal Bank of Canada now owns 271,451 shares of the specialty pharmaceutical company’s stock valued at $11,699,000 after buying an additional 240,978 shares in the last quarter. Hedge funds and other institutional investors own 98.22% of the company’s stock.

Several analysts have issued reports on SUPN shares. Zacks Investment Research cut Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 10th. FBR & Co started coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They issued a “buy” rating and a $53.00 target price for the company. Piper Jaffray Companies restated a “hold” rating and issued a $45.00 target price on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Stifel Nicolaus upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a report on Tuesday, November 7th. Finally, Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 23rd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $49.60.

Supernus Pharmaceuticals Inc (NASDAQ SUPN) opened at $38.00 on Wednesday. Supernus Pharmaceuticals Inc has a 12 month low of $23.10 and a 12 month high of $50.04. The company has a market capitalization of $1,950.00, a price-to-earnings ratio of 37.41, a PEG ratio of 1.68 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. The company’s revenue for the quarter was up 41.5% on a year-over-year basis. research analysts predict that Supernus Pharmaceuticals Inc will post 1.07 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://www.com-unik.info/2017/12/20/allianz-asset-management-gmbh-reduces-position-in-supernus-pharmaceuticals-inc-supn.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit